Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Novo Nordisk

499.8

 

DKK

 

-2.46 %

Less than 1K followers

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
-2.46%
-23.93%
-19.93%
-19.72%
-40.13%
-44.13%
+39.3%
+174.13%
+40,044.58%

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
2.23T DKK
Turnover
2.27B DKK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
27.3.
2025

General meeting '25

28.3.
2025

Half year dividend

7.5.
2025

Interim report Q1'25

All
Press releases
ShowingAll content types
Press release3/24/2025, 10:01 AM

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Novo Nordisk
Regulatory press release3/10/2025, 10:23 AM

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk
Regulatory press release2/27/2025, 2:03 PM

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Novo Nordisk

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release2/7/2025, 12:54 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk
Press release2/7/2025, 7:45 AM

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Novo Nordisk
Regulatory press release2/6/2025, 9:12 AM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk
Press release2/5/2025, 12:36 PM

Novo Nordisk files annual report with the SEC

Novo Nordisk
Regulatory press release2/5/2025, 6:30 AM

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Novo Nordisk
Regulatory press release2/4/2025, 12:57 PM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release1/27/2025, 1:04 PM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release1/24/2025, 10:19 AM

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk
Regulatory press release1/20/2025, 2:32 PM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release1/17/2025, 12:11 PM

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Novo Nordisk
Press release1/8/2025, 11:30 AM

Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases

Novo Nordisk
Regulatory press release12/20/2024, 12:47 PM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Regulatory press release12/20/2024, 10:41 AM

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial

Novo Nordisk
Regulatory press release12/18/2024, 1:59 PM

The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed

Novo Nordisk
Regulatory press release12/16/2024, 12:51 PM

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release12/16/2024, 6:29 AM

Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

Novo Nordisk
Regulatory press release12/14/2024, 5:08 AM

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Novo Nordisk
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.